Okt3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

Daniel Portela, Robin Patel, Jeffrey J. Larson-Keller, Duane M. Ilstrup, Russell H. Wiesner, Jeffery L. Steers, Ruud A.F. Krom, Carlos V. Paya

Research output: Contribution to journalArticle

114 Scopus citations

Abstract

The role of OKT3 monoclonal antibody administration was studied as a risk factor for symptomatic cytomegalovirus (CMV) infection in 229 consecutive liver transplant recipients not receiving specificCMV prophylaxis. Twenty-six patients (11.4%) receivedOKT3 and 17 ofthem developed CMV infection, 11 (4.8%) being symptomatic. OKT3 use was a significant risk factor for symptomatic CMV infection by both univariate (relative risk [RR], 2.9; 95% confidence interval [CI], 1.5-5.8; P =.002) and multivariate time-dependent (RR, 3.4; 95% CI, 1.7-7.1; P =.001) analyses. A subgroup analysis revealed that OKT3 use was a significant risk factor for symptomatic CMV infection in CMV-seropositive but not seronegative recipients. OKT3 therapy for steroid-resistant rejection is a risk factor for symptomatic CMV infection in liver transplant recipients who are seropositive for CMV before transplantation. This group should be targeted for antiviral prophylaxis when OKT3 antirejection therapy is used.

Original languageEnglish (US)
Pages (from-to)1014-1018
Number of pages5
JournalJournal of Infectious Diseases
Volume171
Issue number4
DOIs
StatePublished - Apr 1995

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Okt3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation'. Together they form a unique fingerprint.

  • Cite this

    Portela, D., Patel, R., Larson-Keller, J. J., Ilstrup, D. M., Wiesner, R. H., Steers, J. L., Krom, R. A. F., & Paya, C. V. (1995). Okt3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. Journal of Infectious Diseases, 171(4), 1014-1018. https://doi.org/10.1093/infdis/171.4.1014